SCHEMBL5160134

SCHEMBL5160134

CCOC(=O)c1cc2c(OC)cc3ccccc3c2n1Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
PLA2G10 O15496 2/20 0.53
PLA2G1B P04054 2/20 0.53
PLA2G2A P14555 2/20 0.53
PLA2G2E Q9NZK7 2/20 0.53
PLA2G2D Q9UNK4 2/20 0.53
NOD2 Q9HC29 1/20 0.52
NOD1 Q9Y239 1/20 0.52
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 2/20 0.50
POLB P06746 2/20 0.50
ATM Q13315 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
F10 P00742 3/20 0.49
ALOX5 P09917 1/20 0.46
PLA2G5 P39877 1/20 0.45
PLA2G2F Q9BZM2 1/20 0.45
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14608289 0.90 KMT2A (0.48) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5158136 0.90 KMT2A (0.48) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5162898 0.88 PLA2G10 (0.55) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5160158 0.86 PLA2G10 (0.54) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL14608171 0.86 KMT2A (0.46) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL5159760 0.81 KMT2A (0.49) KMT2APLA2G1BPLA2G2ANOD2NOD1
SCHEMBL6337277 0.81 KMT2A (0.52) KMT2APLA2G2ANOD2NOD1MAPT
SCHEMBL5162302 0.78 PLA2G10 (0.54) KMT2APLA2G10PLA2G1BPLA2G2APLA2G2E
SCHEMBL6765270 0.77 MAPT (0.56) KMT2ANOD2NOD1MAPTALDH1A1
SCHEMBL4798323 0.75 NOD2 (0.85) KMT2ANOD2NOD1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
EP-1358156-B1 BENZ(G) INDOLES AND THEIR USE AS SPLA2 INHIBITORS LILLY CO ELI (US) 2007-02-21 EP disclosed
US-6916840-B2 Spla2 inhibitors ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-20040063967-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063967-A1 Novel spla2 inhibitors PLA2G12A, SPINT2, PLA2G4A KMT2A 2957/4885PLA2G10 18/4885PLA2G1B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.